Key Highlights

  • Oxford Nanopore Technologies Plc (LSE:ONT) rose 5.09% on 6 October 2026, building on a sharp rally that lifted the shares to a 12-month high of 237p last week.
  • The stock has roughly doubled from its July low of around 96p, helped by improving margins, a new 2030 Revenue target and a string of broker upgrades.
  • A preliminary injunction from the Unified Patent Court against MGI Tech GmbH in September reinforced the company's intellectual property moat.
  • First-half 2026 revenue rose 10.5% to £116.7 million, gross Margin expanded 400 basis points to 62.2% and the adjusted EBITDA loss more than halved.
  • Management reiterated targets for adjusted EBITDA breakeven in FY27, positive free Cash Flow in FY28 and revenue above $700 million by 2030.

Oxford Nanopore Technologies Plc (LSE:ONT) Keeps Climbing

Oxford Nanopore Technologies Plc (LSE:ONT) added 5.09% on Tuesday, 6 October 2026, making it one of the strongest risers in the FTSE 250. The gain extends a remarkable run for the Oxford-based gene sequencing pioneer, whose shares jumped more than 20% over the course of last week and touched a 12-month high of 237p on Friday.

The move came as global equities were buoyed by a technology-led rally on Wall Street, and the stock has become one of the most talked-about UK turnaround stories on Social Media and trading forums.

Broker Upgrades Drive a Re-Rating

A key reason Oxford Nanopore Technologies Plc (LSE:ONT) is in focus is the shift in analyst sentiment. In late September, Deutsche Bank raised its price target to 210p from 195p while maintaining a Buy rating. The stock has since moved decisively above that level, which many traders read as a sign that the market is pricing in further upside. Panmure Liberum upgraded the shares to Buy from Hold earlier in the quarter with a 196p target, citing the company's new strategic direction as addressing key investor concerns.

Breaking through multiple broker targets often triggers further upward revisions.

Patent Victory Strengthens the Competitive Moat

Another catalyst came from the courts. On 16 September 2026 the Unified Patent Court granted Oxford Nanopore a preliminary injunction against MGI Tech GmbH. The win reassures investors that Oxford Nanopore Technologies Plc (LSE:ONT) can defend its distinctive nanopore technology in key markets.

The company also announced a global cross-licensing agreement alongside its half-year results, which is expected to generate $20 million of non-recurring revenue in FY26 at a 100% gross margin, plus potential Royalty income in later years. That deal underlines the commercial value of the group's patent estate.

Interim Results Showed Clear Progress on Profitability

The fundamental backdrop has improved meaningfully. For the six months to 30 June 2026, revenue rose 10.5% to £116.7 million, or 12.3% at constant currency. Gross margin expanded by 400 basis points to 62.2%, helped by flow cell Yield improvements, scale benefits and wider adoption of a new pricing model. The adjusted EBITDA loss more than halved to £22.1 million from £48.3 million, and the overall loss for the period narrowed to £48.0 million from £71.8 million.

Clinical revenue rose 35.4% to £17.6 million, making it the fastest-growing customer segment, while biopharma revenue grew 25% to £9.5 million. Research revenue, still the largest segment, increased 5.4% to £76 million.

There were soft spots. Revenue in China fell around 16% and the Middle East declined around 14%, which led to first-half revenue coming in below management's internal expectations. However, outside China and the Middle East, constant currency growth was 16%, and the market has largely looked through these regional issues given the margin progress.

New 2030 Ambition Under CEO Francis Van Parys

Chief executive Francis Van Parys, who succeeded co-founder Gordon Sanghera earlier this year, has reset the strategy around commercially ready markets. Oxford Nanopore Technologies Plc (LSE:ONT) set a new target of more than $700 million of revenue by 2030, based on organic constant currency growth of around mid-teens per annum and accelerating. It also targets an adjusted EBITDA margin above 15% by 2030.

Guidance for FY26 was maintained at 16% to 20% constant currency revenue growth, excluding the licensing income, with gross margin of around 62%. Adjusted operating cost growth guidance was cut to between minus 2% and zero, from a previous range of zero to 5%, demonstrating tighter cost discipline. The company continues to target adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28.

IP Group Sale Removes an Overhang

Last week, long-standing Shareholder IP Group sold 10 million Oxford Nanopore shares at around 210p, raising approximately £21 million. The sale was absorbed easily, and IP Group agreed to a 90-day lock-up on its remaining direct holding of 70.8 million shares, equal to about 7.23% of the company. Traders noted that this lock-up effectively clears a potential near-term Supply overhang until around the turn of the year.

Why the Stock Moved Up Today

The 5.09% rise in Oxford Nanopore Technologies Plc (LSE:ONT) on 6 October reflected strong momentum buying after last week's breakout, a supportive backdrop for technology and life science Growth Stocks following gains on the Nasdaq, and continued enthusiasm around the company's path to profitability.

What to Watch Next

Investors will be watching for further broker target upgrades, any additional licensing or Partnership agreements, updates on regulated clinical products and signs of stabilisation in China. Second-half trading is expected to be stronger than the first half, and any pre-close trading update around the turn of the year will be a key test of the new management team's credibility. For now, Oxford Nanopore Technologies Plc (LSE:ONT) has become one of the most compelling momentum stories in the UK healthcare sector.